[
  {
    "ref_criterion": "Explains that the main goal of bridging therapy is to minimize the risk of PML while preventing clinical and/or radiological relapse of MS during the interval between discontinuation of natalizumab and the onset of action of ocrelizumab.",
    "ref_axis": "accuracy",
    "ref_point": 8,
    "gen_criterion": "Incorrectly states that ocrelizumab is a suitable alternative to natalizumab for all patients",
    "gen_axis": "accuracy",
    "gen_point": -9,
    "similarity": 0.6731,
    "point_diff": 17,
    "score": 0.0,
    "similar_match": true,
    "axis_match": true
  },
  {
    "ref_criterion": "States that a 4- to 6-week interval is usually recommended for switching from natalizumab to ocrelizumab, as a gap that is too long increases the risk of relapse, while a gap that is too short may lead to overlapping side effects and complications.",
    "ref_axis": "accuracy",
    "ref_point": 8,
    "gen_criterion": "Mentions the importance of considering individual patient factors when transitioning from natalizumab to ocrelizumab",
    "gen_axis": "context_awareness",
    "gen_point": 8,
    "similarity": 0.7458,
    "point_diff": 0,
    "score": 0.746,
    "similar_match": true,
    "axis_match": false
  },
  {
    "ref_criterion": "Provides a direct switching protocol from natalizumab to ocrelizumab: last natalizumab infusion \u2192 6-week pause \u2192 first ocrelizumab dose; monitoring at weeks 4 and 6 with MRI \u00b1 CSF (if there is even minimal suspicion).",
    "ref_axis": "accuracy",
    "ref_point": 7,
    "gen_criterion": "Mentions the importance of considering individual patient factors when transitioning from natalizumab to ocrelizumab",
    "gen_axis": "context_awareness",
    "gen_point": 8,
    "similarity": 0.7673,
    "point_diff": 1,
    "score": 0.767,
    "similar_match": true,
    "axis_match": false
  },
  {
    "ref_criterion": "States that in cases of active MRI findings or a history of rapid relapses, clinicians may use short-acting bridging therapy, such as oral corticosteroids (e.g., methylprednisolone), interferons, or glatiramer acetate. Some centers administer a loading dose of ocrelizumab (300 mg) as early as 4 weeks after the last natalizumab infusion, with further management adjusted based on clinical status and neuroimaging.",
    "ref_axis": "accuracy",
    "ref_point": 7,
    "gen_criterion": "Incorrectly states that ocrelizumab is a suitable alternative to natalizumab for all patients",
    "gen_axis": "accuracy",
    "gen_point": -9,
    "similarity": 0.7115,
    "point_diff": 16,
    "score": 0.0,
    "similar_match": true,
    "axis_match": true
  },
  {
    "ref_criterion": "Recommends a baseline MRI before the last natalizumab infusion and a follow-up MRI immediately before initiating ocrelizumab in cases of bridging therapy. Additionally, for patients at increased risk of PML, lumbar puncture with JC-PCR testing is recommended.",
    "ref_axis": "accuracy",
    "ref_point": 7,
    "gen_criterion": "Incorrectly states that ocrelizumab is a suitable alternative to natalizumab for all patients",
    "gen_axis": "accuracy",
    "gen_point": -9,
    "similarity": 0.6238,
    "point_diff": 16,
    "score": 0.0,
    "similar_match": true,
    "axis_match": true
  },
  {
    "ref_criterion": "Explains that currently there are no official unified guidelines for specific \"bridging therapy\" protocols; suggests reviewing the latest publications and consensus documents and discussing the strategy with colleagues.",
    "ref_axis": "accuracy",
    "ref_point": 6,
    "gen_criterion": "Provides a clear explanation of the bridging therapy concept, including the potential risks and benefits",
    "gen_axis": "completeness",
    "gen_point": 9,
    "similarity": 0.7963,
    "point_diff": 3,
    "score": 0.796,
    "similar_match": true,
    "axis_match": false
  },
  {
    "ref_criterion": "Provides a fixed treatment scheme for a patient with moderate MS activity without considering additional data or the individual clinical picture.",
    "ref_axis": "context_awareness",
    "ref_point": -7,
    "gen_criterion": "Incorrectly states that JC-virus is always present in patients with MS",
    "gen_axis": "accuracy",
    "gen_point": -7,
    "similarity": 0.4733,
    "point_diff": 0,
    "score": 0.473,
    "similar_match": false,
    "axis_match": false
  },
  {
    "ref_criterion": "Does not describe various bridging therapy strategies for MS patients and only gives the direct switching protocol from natalizumab to ocrelizumab.",
    "ref_axis": "completeness",
    "ref_point": -6,
    "gen_criterion": "Incorrectly states that ocrelizumab is a suitable alternative to natalizumab for all patients",
    "gen_axis": "accuracy",
    "gen_point": -9,
    "similarity": 0.7359,
    "point_diff": 3,
    "score": 0.736,
    "similar_match": true,
    "axis_match": false
  }
]